The Korea Exchange has decided to keep its listing on Samsung Bio Logics, which has been on the brink of abolishing the listing due to the misdemeanor accounting of up to 4.5 trillion won.

Today (11th) morning, the trading of Samsung Bio stock in the securities market resumed. Samsung Biotech, which was out of the crisis, showed a sharp rise in early 20%.
When the SEC filed a complaint with Samsung Bio on charges of misrepresentation of accounting for less than a week, it came to the conclusion that the background is attracting attention.

The judge said, "Despite some insufficient management transparency, we have no concern about the continuity of the company and the financial situation is stable."

Concerned with the company's continuity, Samsung Biotech's sales and profitability improvement has been confirmed, and considering the business outlook, order backlog and order-taking plan, we have no serious concerns about the continuity of the company. "

Regarding "financial stability," he said, "We did not think that there would be a real possibility that default would become a reality within a considerable period of time."

However, "transparency in management" is based on the "governance structure and internal control system in the law, but it seems that the management transparency is insufficient in some ways, such as the extraordinary accounting by the Supervisor." The Korea Exchange is planning to check Samsung Biotech's management transparency for the next three years by strengthening its practical audit function.

In accordance with the "Fairness Eligibility Guidelines", the corporate judging committee examines financial soundness, corporate continuity, corporate governance and internal control system, and whether the disclosure system is seriously damaged, rather than accounting irregularity.

There are no cases in which 16 listed companies have been delisted due to the violation of the accounting standard after the introduction of the 2009 fair listing system.
Samsung Biotech will continue to be listed on the decision, but the financial authorities' prosecution charges and suspected disciplinary decisions are still valid.

At the end of last month, Samsung Biotech filed an application for suspension and canceled administrative lawsuits against the financial authorities' suspension of transactions. There will be a questioning of the injunction on the 19th.

If the court does not accept the preliminary injunction, Samsung Bio will have to propose the CEO's dismissal early next year.

However, if the disposition application is cited, the disposition of the Securities and Futures Commission will be suspended until the final judgment of the administrative litigation is reached.

It is 'news pick'.

(Photo: Yonhap News)